ConductScience.org, home

Comparison · NCT02508194-4fbcec09

Placebo + IIV vs MEDI7510 + IIV: Number of Participants With Treatment-Emergent Adverse Events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Placebo + IIV vs MEDI7510 + IIV: Number of Participants With Treatment-Emergent Adverse Events. Trial comparisons, record NCT02508194-4fbcec09. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02508194-4fbcec09

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1490.1280.173wilson
Risk in group 20.1540.1330.179wilson
Risk difference, group 1 minus group 2-0.0056-0.0380.0268newcombe hybrid score
Risk ratio, group 1 over group 20.9640.7791.19log
Odds ratio, group 1 over group 20.9570.7451.23log
Number needed to treat, for one fewer participant with the outcome on Placebo + IIV than on MEDI7510 + IIV179from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Placebo + IIVParticipants received a single IM injection of placebo (matched with MEDI7510) in one arm and single IM injection of IIV in the contralateral arm.141948OG000
Group 2MEDI7510 + IIVParticipants received a single IM injection of MEDI7510 in one arm and single IM injection of IIV in the contralateral arm.146946OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Treatment-Emergent Adverse Events
Description
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent events were between administration of study drug and Day 29 that were absent before treatment or that worsened relative to pre-treatment state.
Time frame
Day 1 (post-dose) through Day 29
Population
ATP: Participants who received any dose of IP. Participants were included in the ATP according to the IP received even if different from that to which the participant was randomized.

Source ClinicalTrials.gov

Trial

Title
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
NCT number
NCT02508194
Phases
PHASE2
Conditions
Respiratory Syncytial Virus
Interventions
MEDI7510, IIV, Placebo
Lead sponsor
MedImmune LLC
Results first posted
2017-12-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02508194-4fbcec09